Navigation Links
Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan
Date:4/6/2009

Company extends the term and expands territorial rights of its exclusive licensee in Japan after Itochu reaches market penetration milestone of 100 customer manufacturers in Japan for cosmeceutical and dietary supplement products using patented AC-11(R) (formerly known as C-Med- 100(R))

Increase in consumer demand fueled by results of new research showing that that orally administered AC-11(R) supplement increases the production of collagen III in the epidermis layer of the skin.

NEW YORK, April 6 /PRNewswire-FirstCall/ -- Optigenex Inc. (Pink Sheets: OPGX) announced today the signing of an extended and expanded new contract with its distribution partner in Asia (Itochu Corporation). Under the new license, Itochu has the right to market AC-11(R) technology exclusively in Japan and non-exclusively throughout the rest of Asia (Additional details were not disclosed). The new agreement represents the fulfillment of an important strategic objective to the company in terms of its business development plans for the Asia and further validates its business model in Japan and other countries in the region.

To date, Itochu has introduced AC-11(R) to over 100 companies in the cosmetic and dietary supplement market, with over 130 products containing AC-11(R) being marketed and sold. AC-11(R) is a patented, all-natural rain forest botanical extract that helps the body's natural ability to repair damage to its own DNA due to multiple causes, including harmful effects of UV radiation from over exposure to the sun, stress, environmental pollution and other toxins. In its standard bulk powder form, AC-11(R) supplement may be consumed orally or combined with liposomes and other delivery mechanisms for topical application on the skin.

The increase in demand for AC-11(R)-based products follows the issuance of a report in October 2008 by a leading French dermatological research center showing that orally administered AC-11(R) supplement increases the production of collagen III in the epidermis layer of the skin by stimulating expression of the COL3A1 gene. Collagen III is important for the development of skin and the cardiovascular system and for maintaining normal physiological functions in adult life. Results of the study suggest that oral and topical AC-11(R) products, when combined, are an inner and outer beauty solution to help reverse the signs of premature aging.

The French research, which was sponsored by Itochu, compliments earlier published third party studies demonstrating the effectiveness of AC-11(R) as a unique DNA repair adjuvant, as well as a natural inhibitor of pro-inflammatory agents and a natural immune system supporter.

Itochu partners with Optigenex under an Exclusive Supply and Trademark Licensing Agreement to market AC-11(R) bulk material and consumer products containing AC-11(R) under sublicenses in Japan and several other Asian countries.

Daniel Zwiren, president and CEO of Optigenex Inc. said, "We are excited by our new agreement with Itochu and equally with the results of the French laboratory study and by Itochu's joint commitment with us to expand the science behind AC-11(R). The personal care products market in Japan and the rest of Asia continues to grow. With Itochu's efforts, we are confident that Optigenex and AC-11(R) will be part of that growth."

Yusuke Itou of Itochu Corporation added the following, "We are very pleased with the positive reception AC-11(R) has received from manufacturers in Japan and our expanding role in marketing AC-11(R) in Southeast Asia. We anticipate strong demand for additional AC-11(R)-based products in the remainder of 2009 and beyond as consumer awareness of the benefits of AC-11(R) for healthy DNA maintenance and natural skin collagen production increases."

About ITOCHU Corporation:

Itochu Corporation is one of Japan's leading trading companies and is engaged in a wide variety of businesses, including food products, personal care products, textiles, technology multimedia, metals, energy, chemicals, forest products, retail and financial services. Itochu has approximately 45,690 employees maintains over 130 offices and owns over 651 subsidiaries and affiliates around the world. Itochu's sales last year reached 11.58 trillion yen (U.S. $95 billion.) (Update sales revenue and company figures)

About Optigenex Inc.:

Optigenex inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring AC-11(R) (Formerly known as C-MED-100(R)) a patented compound as it core product. AC- 11(R) is the bioactive, water soluble form of the medicinal herb Uncaria tomentosa. For more information about Optigenex please email the company at: dzwiren@optigenex.com


'/>"/>
SOURCE Optigenex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
2. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
3. Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
4. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
5. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
6. Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials
7. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
8. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
9. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 26, 2016 Story Highlights: ... models within the health care industry is causing providers ... , Deloitte offers a suite of solutions for ... impacting efficient cost optimization: labor resource analysis, revenue cycle ... facilitate better outcomes and better economics ...
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... TherapySites, the leading website ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to ... adding exclusive benefits and promotional offers. , "TCA is extremely excited about this ...
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
Breaking Medicine News(10 mins):